MYCOF — Mydecine Innovations Cashflow Statement
0.000.00%
Last trade - 00:00
- $0.67m
- $4.66m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -13.4 | -3.51 | -26.9 | -23.6 | -17.2 |
Depreciation | |||||
Non-Cash Items | 9.85 | 1.71 | 18 | 3.89 | 0.474 |
Discontinued Operations | |||||
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.505 | 0.2 | 1.77 | -4.59 | 8.21 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -3.99 | -1.49 | -7.12 | -24.1 | -8.43 |
Capital Expenditures | -0.009 | 0 | -0.405 | -0.291 | 0 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.252 | 0.055 | -0.168 | -0.182 | -0.038 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.261 | 0.055 | -0.573 | -0.474 | -0.038 |
Financing Cash Flow Items | 0.219 | 0 | — | -0.76 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.94 | 1.43 | 9.92 | 23.8 | 6.98 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.36 | 0.007 | 2.17 | -0.695 | -1.48 |